The World Health Organization (WHO) declared the monkeypox outbreak a "public health emergency of international concern" on August 14, 2024. This is the second time since July 2022 that WHO has issued the highest level of alert on the monkeypox outbreak, which has attracted great attention from the international community. At the same time, WHO data shows that the number of monkeypox cases reported so far this year has exceeded the total number of cases last year, with 537 deaths.

Human monkeypox virus (MPXV) is a double-stranded DNA virus of the genus Orthopoxvirus of the Poxviridae family. Two genetic clades of monkeypox virus have been characterized: West Africa (CFR 10%) and Congo Basin (CFR 3.6%). The virus will produce two different forms of virus particles with infection ability in the host, which have the Extracellular Enveloped Virion (EEV) with a double-layer membrane structure and the Intracellular Enveloped Virion (IMV) with a single-layer membrane structure.

As a company focused on the development and service of innovative antibody drugs, Sanyou Bio will launch a series of monkeypox related products in response to the needs of global epidemic. A total of 65 related products will be launched, including 11 cell lines, 26 antigens and 28 monoclonal antibodies, covering A29L, M1R, H3L, E8L, A35R, B6R on the surface of monkeypox virus and A28L, A30L, B21R, L1R and I1L involved in monkeypox virus infection and assembly. The launch of Sanyou Bio monkeypox virus series products will help the research in different directions such as vaccines, drugs and diagnostic reagents, from antibody screening to activity verification, as well as the identification of potential unknown receptors as bait cells, and will accelerate the exploration of the unknown world of monkeypox virus.